New and improved tests allow patients to access effective treatment through earlier diagnosis
Over 6 million people are affected by neurodegenerative diseases in the EU and this number is set to double over the next 20 years. Early diagnosis of Alzheimer’s disease, the most common form of neurodegeneration, can help patients access effective treatments and sources of support, but studies suggest only half of people with the condition have been diagnosed and these cases are often only identified in the advanced stages. One of the key reasons for this is the lack of accuracy involved in the measurement of biomarkers used to indicate Alzheimer’s disease. This project used the achievements of EMRP project HLT05 Metallomics to improve this accuracy by establishing new reference measurement procedures for established biomarkers in cerebrospinal fluid, found in the brain and spine, while also introducing procedures for potential new blood-based biomarkers. This has supported reliable, comparable measurements in current diagnostic tests and further the development of population-based screening through blood testing, which is urgently required to enable earlier diagnosis of Alzheimer’s disease.
Journal of Analytical Atomic Spectrometry
Journal of Biophotonics
Neurology - Neuroimmunology Neuroinflammation
BMC Research Notes